Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Int’l Convention at San Diego, June 19-22 <contact info>                     Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Int’l Convention at San Diego, June 19-22 <contact info>                     Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Int’l Convention at San Diego, June 19-22 <contact info>                     Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Int’l Convention at San Diego, June 19-22 <contact info>                    
 
Home      About      Team      Clients      Publications      Downloads      News      Contact            

Testimonials
  Through its 'Corporate Partnership Program', Bioscience Valuation has provided exceptional support in the transformation of our business model. BSV's evidence-based assessments proved invaluable for our strategic decision making as well as for preparing our corporate transactions.

Peter Llewellyn-Davies, CFO/CBO
Medigene AG

 

Core Services
  Financial Valuation
  Commercial Assessment &
Pharmacoeconomics

  R&D Risk Analysis &
Productivity Increase

  Portfolio Management
  Investment Decisions
  Partnering / Licensing
  Corporate Finance / M&A

Special Expertise
  Economic Modeling
of Healthcare Systems

  Assessing the Economics
of Personalized Medicine

Comprehensive Support
  Corporate Partnership Program

Products
  Market Model
  R&D Risk Model
  Valuation Model

Core Services - Investment Decisions

Investment Decisions shall be driven by thorough analyses that integrate
  • all commercial aspects including a drug's current and future competitive environment as well as pharmacoeconomics (also see > Commercial Assessment),
  • the analysis and mitigation of development risk (also see > R&D Productivity Increase),
  • the identification of a company's cost of capital,
  • the calculation of risk-adjusted net present values ('NPVs'),
  • the assessment how value is expected to increase once set milestones have been reached,
  • 'comparables', i.e. market transactions with a known value.

Bioscience Valuation supports management with comprehensive analyses and clear investment recommendations that can be shared with any stakeholder.


Case:
A 'top 25' pharma company wished to improve its project prioritization metrics. Bioscience Valuation implemented its valuation methodology by educating the company's newly formed portfolio management team.

A transparent, value-driven prioritization process was tailored to the organiation involving all functions and management levels, including the CEO.